Antibe Therapeutics Inc (CVE:ATE) Director Nicolas Bourgeois acquired 100,000 shares of Antibe Therapeutics stock in a transaction dated Tuesday, September 18th. The shares were bought at an average price of C$0.26 per share, with a total value of C$26,000.00.

ATE traded down C$0.01 during trading on Friday, hitting C$0.30. The stock had a trading volume of 521,900 shares, compared to its average volume of 1,232,811. Antibe Therapeutics Inc has a twelve month low of C$0.08 and a twelve month high of C$0.79.

Antibe Therapeutics (CVE:ATE) last posted its quarterly earnings results on Wednesday, August 29th. The company reported C($0.01) earnings per share for the quarter, topping the Zacks’ consensus estimate of C($0.02) by C$0.01. Antibe Therapeutics had a negative net margin of 94.01% and a negative return on equity of 130.60%. The business had revenue of C$2.54 million for the quarter, compared to analysts’ expectations of C$2.30 million.

About Antibe Therapeutics

Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.

Featured Article: Fundamental Analysis – How It Helps Investors

Insider Buying and Selling by Quarter for Antibe Therapeutics (CVE:ATE)

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with's FREE daily email newsletter.